Cargando…
Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections
OBJECTIVES: Our study aimed to evaluate the real-world data on renal and neurological adverse effects and effectiveness of colistimethate sodium (CMS) and polymyxin B (PMB). MATERIALS AND METHODS: An observational prospective study was performed on inpatients receiving CMS and PMB for multidrug-resi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657617/ https://www.ncbi.nlm.nih.gov/pubmed/37737075 http://dx.doi.org/10.4103/ijp.ijp_762_20 |
_version_ | 1785137258071851008 |
---|---|
author | Simon, Veneta Viswam, Aathira Alexander, Pallavi Sarah James, Emmanuel Sudhindran, S. |
author_facet | Simon, Veneta Viswam, Aathira Alexander, Pallavi Sarah James, Emmanuel Sudhindran, S. |
author_sort | Simon, Veneta |
collection | PubMed |
description | OBJECTIVES: Our study aimed to evaluate the real-world data on renal and neurological adverse effects and effectiveness of colistimethate sodium (CMS) and polymyxin B (PMB). MATERIALS AND METHODS: An observational prospective study was performed on inpatients receiving CMS and PMB for multidrug-resistant Gram-negative bacterial infections. CMS dose was titrated to renal function, and serum creatinine was assessed daily. The incidence of nephrotoxicity, the primary outcome, was evaluated based on an increase in serum creatinine from baseline as well as by the Risk, Injury, Failure, Loss of kidney function, and End-stage renal disease criteria. Neurological adverse effects were assessed based on clinical signs and symptoms, and the causality and severity were assessed by the Naranjo scale and modified Hartwig–Siegel scale, respectively. The effectiveness of polymyxin therapy was ascertained by a composite of microbiological eradication of causative bacteria and achievement of clinical cure. Thirty-day all-cause mortality was also determined. RESULTS: Between CMS and PMB, the incidence of nephrotoxicity (59.3% vs. 55.6%, P = 0.653) or neurotoxicity (8.3% vs. 5.6%, P = 0.525) did not significantly differ. However, reversal of nephrotoxicity was significantly more with patients receiving CMS than PMB (48.4% vs. 23.3%, P = 0.021). Favorable clinical outcomes (67.6% vs. 37%, P < 0.001) and microbiological eradication of causative bacteria (73.1% vs. 46.3%, P = 0.001) were significantly more with CMS than PMB. Patients treated with CMS had lower all-cause mortality than those with PMB treatment (19.4% vs. 42.6%, P = 0.002). CONCLUSION: There is no significant difference in the incidence of renal and neurotoxic adverse effects between CMS and PMB when CMS is administered following renal dose modification. CMS shows better effectiveness and lower mortality compared to PMB. |
format | Online Article Text |
id | pubmed-10657617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-106576172023-07-01 Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections Simon, Veneta Viswam, Aathira Alexander, Pallavi Sarah James, Emmanuel Sudhindran, S. Indian J Pharmacol Research Article OBJECTIVES: Our study aimed to evaluate the real-world data on renal and neurological adverse effects and effectiveness of colistimethate sodium (CMS) and polymyxin B (PMB). MATERIALS AND METHODS: An observational prospective study was performed on inpatients receiving CMS and PMB for multidrug-resistant Gram-negative bacterial infections. CMS dose was titrated to renal function, and serum creatinine was assessed daily. The incidence of nephrotoxicity, the primary outcome, was evaluated based on an increase in serum creatinine from baseline as well as by the Risk, Injury, Failure, Loss of kidney function, and End-stage renal disease criteria. Neurological adverse effects were assessed based on clinical signs and symptoms, and the causality and severity were assessed by the Naranjo scale and modified Hartwig–Siegel scale, respectively. The effectiveness of polymyxin therapy was ascertained by a composite of microbiological eradication of causative bacteria and achievement of clinical cure. Thirty-day all-cause mortality was also determined. RESULTS: Between CMS and PMB, the incidence of nephrotoxicity (59.3% vs. 55.6%, P = 0.653) or neurotoxicity (8.3% vs. 5.6%, P = 0.525) did not significantly differ. However, reversal of nephrotoxicity was significantly more with patients receiving CMS than PMB (48.4% vs. 23.3%, P = 0.021). Favorable clinical outcomes (67.6% vs. 37%, P < 0.001) and microbiological eradication of causative bacteria (73.1% vs. 46.3%, P = 0.001) were significantly more with CMS than PMB. Patients treated with CMS had lower all-cause mortality than those with PMB treatment (19.4% vs. 42.6%, P = 0.002). CONCLUSION: There is no significant difference in the incidence of renal and neurotoxic adverse effects between CMS and PMB when CMS is administered following renal dose modification. CMS shows better effectiveness and lower mortality compared to PMB. Wolters Kluwer - Medknow 2023 2023-09-11 /pmc/articles/PMC10657617/ /pubmed/37737075 http://dx.doi.org/10.4103/ijp.ijp_762_20 Text en Copyright: © 2023 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Research Article Simon, Veneta Viswam, Aathira Alexander, Pallavi Sarah James, Emmanuel Sudhindran, S. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections |
title | Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections |
title_full | Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections |
title_fullStr | Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections |
title_full_unstemmed | Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections |
title_short | Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections |
title_sort | colistin versus polymyxin b: a pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant gram-negative bacterial infections |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657617/ https://www.ncbi.nlm.nih.gov/pubmed/37737075 http://dx.doi.org/10.4103/ijp.ijp_762_20 |
work_keys_str_mv | AT simonveneta colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections AT viswamaathira colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections AT alexanderpallavisarah colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections AT jamesemmanuel colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections AT sudhindrans colistinversuspolymyxinbapragmaticassessmentofrenalandneurologicaladverseeffectsandeffectivenessinmultidrugresistantgramnegativebacterialinfections |